1
Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine
Stephen J. Thomas, M.D.1 , Edson D. Moreira Jr., M.D.2, Nicholas Kitchin, M.D.3a, Judith
Absalon, M.D.3b, Alejandra Gurtman, M.D.3b, Stephen Lockhart, D.M.3a, John L. Perez, M.D.3c,
Gonzalo Pérez Marc, M.D.4, Fernando P. Polack, M.D.5, Cristiano Zerbini, M.D.6, Ruth Bailey,
B.Sc.3a, Kena A. Swanson, Ph.D.3b, Xia Xu, Ph.D.3c, Satrajit Roychoudhury, Ph.D.7, Kenneth
Koury, Ph.D.3b, Salim Bouguermouh, M.D., Ph.D.3b, Warren V. Kalina, Ph.D.3b, David Cooper,
Ph.D.3b, Robert W. Frenck, Jr., M.D.8, Laura L. Hammitt, M.D.9, Ӧzlem Türeci, M.D.10, Haylene
Nell, M.D.11, Axel Schaefer, M.D.12, Serhat Ünal, M.D.13, Qi Yang, Ph.D.3b, Paul Liberator,
Ph.D.3b, Dina B. Tresnan, D.V.M., Ph.D.14a, Susan Mather, M.D.14b, Philip R. Dormitzer, M.D.,
Ph.D.3b, Uğur Şahin, M.D.10; William C. Gruber, M.D.3b, Kathrin U. Jansen, Ph.D.3b and the
C4591001 Clinical Trial Group
1State University of New York, Upstate Medical University, Syracuse , NY; 2Associação Obras
Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia, Brazil; 3Vaccine Research and
Development, Pfizer Inc, aHurley, UK, bPearl River, NY, cCollegeville, PA; 4 iTrials-Hospital
Militar Central, Buenos Aires, Argentina; 5Fundacion INFANT, Buenos Aires, Argentina;
6Centro Paulista de Investigação Clinica, São Paulo, Brazil; 7Global Product Development,
Pfizer Inc, Peapack, NJ; 8Cincinnati Children’s Hospital, Cincinnati, OH; 9Johns Hopkins
Bloomberg School of Public Health, Baltimore, MD; 10BioNTech, Mainz, Germany; 11Tiervlei
Trial Centre, Karl Bremer Hospital, Cape Town, South Africa; 12Medizentrum Essen Borbeck,
Essen, Germany; 13Hacettepe University, Ankara, Turkey; 14Worldwide Safety, Safety
Surveillance and Risk Management, Pfizer, Inc, aGroton, CT, bCollegeville, PA.
Corresponding Author:
Judith Absalon, M.D., M.P.H., F.I.D.S.A.
Pfizer Inc
401 North Middletown Road
Pearl River, NY 10965
Judith.Absalon@pfizer.com
.
CC-BY-NC-ND 4.0 International license
It is m